脐带间充质干细胞移植治疗慢性肝衰竭

发布时间：2018-02-12 06:41

本文关键词：脐带间质干细胞移植肝功能衰竭肝炎病毒乙型组织工程干细胞移植脐带间充质干细胞慢性肝衰竭乙型肝炎病毒肝功能凝血酶原活动度 MELD评分安全性　出处：《中国组织工程研究》2017年13期 　论文类型：期刊论文

【摘要】：背景:脐带间充质干细胞来源丰富,取材方便,增殖能力强,可以分化为肝细胞,为肝衰竭治疗开辟了新途径。目的:观察脐带间充质干细胞移植治疗慢性肝衰竭的安全性和疗效。方法:慢性肝衰竭患者50例,按平行对照分组方式分为2组:干细胞组25例,在内科综合治疗的基础上给予脐带间充质干细胞移植,经前臂静脉途径输注脐带间充质干细胞(1.4-2.3)×106/kg,总体积100 mL,对照组25例,给予单纯内科综合治疗,输注等体积的生理盐水,每半个月1次,共输注3次。于治疗前、治疗后2,4,12,24周观察患者的肝功能、凝血酶原活动度、MELD评分、临床症状、生存情况及不良反应。结果与结论:(1)干细胞组白蛋白、凝血酶原活动度在治疗后12,24周较对照组明显升高,差异有显著性意义(P0.05);MELD评分在治疗后4,12,24周较对照组明显降低,差异有显著性意义(P0.05);(2)两组丙氨酸转氨酶、总胆红素比较差异无显著性意义(P0.05);(3)治疗4周后,干细胞组临床症状明显改善,与对照组比较差异有显著性意义(P0.05);(4)随访24周,干细胞组生存率高于对照组,差异有显著性意义(P0.05);(5)未出现与干细胞治疗相关的不良反应,无肝癌发生;(6)结果表明,脐带间充质干细胞移植治疗慢性肝衰竭患者安全有效,可明显提高患者生存率。
[Abstract]:Background: umbilical cord mesenchymal stem cells are rich in origin, convenient in taking materials and strong in proliferation, and can be differentiated into hepatocytes. Objective: to observe the safety and efficacy of umbilical cord mesenchymal stem cell transplantation in the treatment of chronic liver failure. Umbilical cord mesenchymal stem cell transplantation was given on the basis of comprehensive medical treatment. Umbilical cord mesenchymal stem cells were infused with umbilical cord mesenchymal stem cells 1.4-2.3 脳 10 ~ (-6) 脳 10 ~ (-6) 路kg 路kg ~ (-1) 脳 10 ~ (-6) 脳 10 ~ (6) 脳 10 ~ (-1) 脳 10 ~ (-1) 脳 10 ~ (-6) 脳 10 ~ (-1) 脳 10 ~ (-1) ml. The liver function, prothrombin activity and meld scores, clinical symptoms, survival conditions and adverse reactions were observed before and 24 weeks after treatment. The prothrombin activity was significantly higher than that in the control group at the 12th week after treatment, and the difference was significant (P 0.05) and the meld score was significantly lower than that in the control group at 24 weeks after treatment, and the difference was significant (P 0.05%) between the two groups, and there was no significant difference between the two groups in alanine aminotransferase (P 0.05), and the activity of prothrombin was significantly higher than that in the control group (P 0.05). There was no significant difference in total bilirubin after 4 weeks of treatment, the clinical symptoms of stem cell group were significantly improved, compared with that of control group, there was a significant difference (P 0.05). The survival rate of stem cell group was higher than that of control group. The results showed that umbilical cord mesenchymal stem cell transplantation was safe and effective in the treatment of patients with chronic liver failure.
【作者单位】：河北医科大学第一医院中西医结合肝病诊疗中心;
【基金】：河北省医学科学研究重点课题(20150636)~~
【分类号】：R575.3

【相似文献】